Catalysts
HRMY Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
HRMYHarmony Biosciences Holdings, Inc.
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum66
- Value89
- Quality77
- Risk resilience63
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 66/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 18.75%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | — | $1.09 | $0.81 | -25.7% | $272.05M | $268.92M |
| Aug 4, 2026 | — | $0.96 | $1.28 | +33.9% | $250.77M | $261.28M |
| May 7, 2026 | — | $0.76 | $0.55 | -27.6% | $220.84M | $215.39M |
| Feb 24, 2026 | — | $0.84 | $0.38 | -54.8% | $240.33M | $243.78M |
| Nov 4, 2025 | — | $0.92 | $0.87 | -5.4% | $240.04M | $239.46M |
| Aug 5, 2025 | — | $0.78 | $0.68 | -12.8% | $220.16M | $200.49M |
| May 6, 2025 | — | $0.59 | $0.78 | +32.2% | $206.05M | $184.73M |
| Feb 25, 2025 | — | $0.74 | $0.85 | +14.9% | $183.21M | $201.27M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -19.00% and -0.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Related Links
HRMY Catalysts FAQ
What are the next catalysts for HRMY stock?
HRMY's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move HRMY stock?
Upcoming events that could move HRMY include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could HRMY's next earnings report affect the stock?
HRMY's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive HRMY stock higher?
HRMY could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt HRMY stock?
HRMY could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.